Status:

TERMINATED

The Role of Hypoxia as a Selective Pressure for TP53 Mutations

Lead Sponsor:

Institute of Cancer Research, United Kingdom

Collaborating Sponsors:

Cancer Research UK

Conditions:

Endometrial Cancer

Eligibility:

FEMALE

18+ years

Brief Summary

The study aims to develop scans that tell the investigators about the oxygen content of tumours using Magnetic Resonance Imaging (MRI) and seeing whether regions of low oxygen content are related to m...

Detailed Description

Cancer tissue harbours a multitude of genetic alterations, and it is well-established that when certain key alterations develop, they are powerful determinants of tumour behaviour (growth rate, potent...

Eligibility Criteria

Inclusion

  • ≥18 years of age on the day of signing the informed consent.
  • Histologically confirmed endometroid or serous endometrial cancer.
  • Scheduled to have hysterectomy at the cancer centre
  • Identifiable tumour mass on staging MRI.
  • Voluntarily agreed to participate by giving written informed consent.

Exclusion

  • Life expectancy of \< 6 months.
  • Ferromagnetic implants, contraindicating MRI
  • Claustrophobia so unable to tolerate MRI
  • Unable to lie flat
  • Ascites sufficient to prevent patient being fitted in the scanner bore
  • Histology unlikely to show variation in TP53 status, or heavily calcified disease.
  • Radiotherapy to the abdomen or pelvis within 6 months of the screening visit.
  • Unresolved bowel obstruction.
  • Currently participating or has participated in a study with an investigational compound or device within 30 days of the start of treatment.
  • History or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with patient's participation for the full duration of the study, or is not in the best interest of the patient to participate.
  • Unlikely to comply with the requirements of the study.

Key Trial Info

Start Date :

February 6 2018

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

July 30 2019

Estimated Enrollment :

5 Patients enrolled

Trial Details

Trial ID

NCT03466034

Start Date

February 6 2018

End Date

July 30 2019

Last Update

January 29 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust

Sutton, Surrey, United Kingdom, SM2 5PT